Be sure to check our website

With the focus on drug delivery can N4 Pharma fill a need in the market?

With a focus on drug delivery N4 Pharma has benefitted from the rise in recent months in the market with talk around the sector and Covid-19. IGTV’s Jeremy Naylor caught up with N4 Pharma’s chief executive Nigel Theobold. N4 is a specialist in drug delivery in order to ensure that the patient receives maximum effectiveness of viral vaccines.

N4 Pharma plc (LON:N4P) are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    DirectorsTalk

    More articles like this

    DirectorsTalk

    N4 Pharma raises £2 million through placing

    9th December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of

    DirectorsTalk

    N4 Pharma update on Nanomerics research collaboration

    3rd December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February

    DirectorsTalk

    N4 Pharma Q&A: Confirming Nuvec’s versatility (LON:N4P)

    12th November 2020

    N4 Pharma’s Nigel Theobald discusses their latest operational update, the importance of demonstrating formulation, key milestones for the COVID-19 proof of concept programme, whyan orally administered vaccine has greater challenges than a subcutaneous injection and what news flow investors can expect from the company for the rest of the year in this exclusive interview with DirectorsTalk.

    DirectorsTalk

    N4 Pharma make significant strides with optimisation work

    5th November 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing work programmes. Optimisation The optimisation programme is investigating different formulations of Nuvec®

    DirectorsTalk

    Emerging vaccine delivery systems for COVID-19

    16th October 2020

    Confirmed COVID-19 cases are in the millions, and with hundreds of thousands of deaths from the disease the social, healthcare and economic consequences are likely to persist for years. While drug treatments may emerge, which reduce the impact of

    © 2020 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited